| Code | CSB-RA004954MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to SEA-CD70, designed for research applications targeting CD70 (CD27 ligand). CD70 is a type II transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) superfamily, expressed transiently on activated T cells, B cells, and dendritic cells. Under normal physiological conditions, CD70 expression is tightly regulated and plays a critical role in T cell activation and differentiation through interaction with its receptor CD27. Aberrant or constitutive CD70 expression has been documented in various hematological malignancies including non-Hodgkin lymphoma, multiple myeloma, and acute lymphoblastic leukemia, as well as in solid tumors such as renal cell carcinoma and glioblastoma, making it an attractive target for cancer research.
SEA-CD70 represents a therapeutic antibody candidate that has been investigated for its potential in targeting CD70-expressing malignancies through antibody-dependent cellular cytotoxicity mechanisms. This biosimilar antibody provides researchers with a valuable tool for investigating CD70 biology, tumor immunology, and mechanisms of antibody-mediated tumor cell elimination in preclinical studies.
There are currently no reviews for this product.